CircoMax Myco

RSS
Authorised
This medicine is authorised for use in the European Union.

Overview

Authorisation details

Product details
Name
CircoMax Myco
Agency product number
EMEA/V/C/005184
Active substance
  • Inactivated Mycoplasma hyopneumoniae, strain P-5722-3
  • Inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (ORF2) protein
  • Inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b ORF2 protein
Species
Pigs (for fattening)
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI09AL08
Publication details
Marketing-authorisation holder
Zoetis Belgium SA 
Date of issue of marketing authorisation valid throughout the European Union
09/12/2020
Contact address

Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

09/12/2020 CircoMax Myco - EMEA/V/C/005184 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals for suidae 

Therapeutic indication

Active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with PCV2 infection. Protection was demonstrated against porcine circovirus types 2a, 2b and 2d.

Active immunisation of pigs against Mycoplasma hyopneumoniae to reduce the lung lesions associated with Mycoplasma hyopneumoniae infection. 

Onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. 

Duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. 

In addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Assessment history

Related content

How useful was this page?

Add your rating